Novavax vaccine needs only standard refrigeration, not freezing or ultracold temperature storage
TUESDAY, Dec. 29, 2020 (HealthDay News) — Vaccine maker Novavax, along with federal health researchers, announced Monday that a phase 3 trial will begin on the safety and effectiveness of another COVID-19 vaccine — the fifth shot to reach this final stage of development.
“We’ve come this far, this fast, but we need to get to the finish line,” Francis Collins, M.D., director of the U.S. National Institutes of Health, said in a statement.
Novavax will enroll 30,000 people from 115 testing sites across the United States and Mexico, and testing is already underway in Britain. The vaccine — which right now is known as NVX-CoV2373 — comes in two doses and is designed to enhance the body’s immune response to the coronavirus spike protein.
The Novavax shot is somewhat different from approved vaccines from Pfizer and Moderna, in that it manufactures its own antigens that mimic the coronavirus spike protein. However, these antigens “cannot replicate and cannot cause COVID-19,” the NIH said in the statement.
If phase 3 trials prove the Novavax vaccine to be safe and effective, the shot has one big advantage over the Moderna and Pfizer vaccines: It needs only standard refrigeration, not the freezing or ultracold temperature storage required by the first two vaccines.
~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2 
Parts of the World Seeing New COVID-19 Variant 
HHS, NIH Unveil Vaccine Initiative to Protect Against Future Pandemics 
Hospital-Onset SARS-CoV-2 Infection During Omicron Linked to Morbidity 
Staffing, Scheduling, and Wage Changes Could Reattract Nurses Back to Hospitals 
Skilled Nursing Facility Capacity Declined Between 2019 and 2024 
Physical Design of Critical Care Units Influences Nursing Culture 
Low Capability Pediatric Hospitals More Than Doubled From 2003 to 2022 
